Paul Crispen

WVU020925: A Multicenter Phase II Study of Subcutaneous Blinatumomab for Treatment of Adult Patients with CD19-Positive Mixed Phenotype Acute Leukemia (MPAL)

Florida Partnership for Adding Social Context to Address Cancer Survivorship Outcomes (ASCENT)

A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)

GAIN-BCG: Gemcitabine Alternating with INtravesical BCG randomized against BCG alone for patients with recurrent high grade Non-Muscle Invasive Bladder Cancer

A Phase 1 Dose Escalation Study of STM-416p Administered Intraoperatively to Patients Undergoing Radical Prostatectomy

Salvage Focal Therapy via High Intensity Focused Ultrasound (HIFU) in Radiorecurrent Localized Prostate Cancer (FocalHIFU) (NCT06402357)

Enhancing Connection and Communication with Community-Based Oncology Practices to Improve Cancer Clinical Trial Recruitment: The ECCO Study

Adstiladrin Early Utilization and Outcomes in the Real World Setting in the United States

PHASE III RANDOMIZED ADJUVANT STUDY OF MK-3475 (PEMBROLIZUMAB) IN MUSCLE INVASIVE AND LOCALLY ADVANCED UROTHELIAL CARCINOMA (AMBASSADOR) VERSUS OBSERVATION

ASCO Screening and Enrollment Qualitative Study

UF Health Cancer Center Support Grant

A Randomized Phase III Trial of Intravesical BCG veRsus Intravesical Docetaxel and GEmcitabine Treatment in BCG Naïve High Grade Non-Muscle Invasive Bladder Cancer (BRIDGE)

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors

A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy

A Phase 2, Open-Label, Multi-Center, Randomized Study of TAR-200 in Combination with Cetrelimab and Cetrelimab Alone in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder who are Scheduled for Radical Cystectomy and are Ineligible for or Refusing Platinum-Based Neoadjuvant Chemotherapy

Phase 1/2, open-label, multicenter study to evaluate a dosing regimen with two step-up priming doses and longer dosing intervals of Elranatamab (PF-06863135) monotherapy in participants with relapsed/refractory multiple myeloma

Parallel Phase III Randomized Trials of Genomic-Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

A phase III, Open-label, Multicenter, Randomized Study Comparing 177Lu-PSMA-617 vs. a change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with progressive Metastatic Castrate Resistant Prostate Cancer#

A phase III, Open-label, Multicenter, Randomized Study Comparing 177Lu-PSMA-617 vs. a change of androgen receptor-directed therapy in the Treatment of Taxane Naïve Men with progressive Metastatic Castrate Resistant Prostate Cancer

Phase III Randomized Trial of DFP-10917 vs. Non-Intensive Reinduction (LoDAC, Azacitidine, Decitabine, Venetoclax Combination Regimens) or Intensive Reinduction (High and Intermediate Dose Cytarabine Regimens) for Acute Myelogenous Leukemia Patients in Second, Third, or Fourth Salvage#

A Phase 3, Randomized, Open-label Study to Evaluate Perioperative Enfortumab Vedotin Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Gemcitabine and Cisplatin in Cisplatin-eligible Participants with Muscle-invasive Bladder Cancer (KEYNOTE-B15 / EV-304)#

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab in Localized Muscle Invasive Bladder Cancer (Study SWOG/NRG S1806)

A Randomized Phase II Trial of Salvage Radiotherapy with Standard vs Enhanced Androgen Deprivation Therapy (with Enzalutamide) in Patients with Post-Prostatectomy PSA Recurrences with Aggressive Disease Features